OSI Pharmaceuticals and AVEO Pharmaceuticals have inked a deal to discover and develop small molecules. The companies hope to develop therapies that target the underlying mechanisms of epithelial-mesenchymal transition in cancer. AVEO gains $10 million upfront and purchase equity valued at approximately $5 million. OSI will also pay AVEO research funding, as well as milestones and royalties for any successful therapies that result from the pact.Â
- see the release on the deal for more
Related Articles:
AVEO designs better mice to trap better therapies. Report
AVEO gains $53M in financing. Report
OSI looks to unload Macugen, exit eye diseases. Report
OSI licenses diabetes drug to Lilly in $385M pact. Report